null Wassim Kassouf, MD
bladder cancer • outcomes • resistance • radiotherapy • response
I am a surgeon-scientist who conducts both clinical and translational research in genitourinary cancers. My laboratory has focused on optimizing bladder-preserving therapies in patients with bladder cancer. We have developed expertise in radiosensitization for invasive bladder cancer, both in preclinical and clinical settings. Bringing novel basic science to clinic and then back has been an approach that our team continues to pursue. Findings from my laboratory have directly translated into four investigator-initiated clinical trials and I currently serve as study chair on the large, potentially practice-changing, randomized clinical trial evaluating radiation with immune checkpoint inhibition in bladder cancer that is activated in Canada, the UK and Spain.
Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. S Shinde-Jadhav, JJ Mansure, RF Rayes, G Marcq, M Ayoub, Skowronski R, Kool R, Bourdeay F, Brimo F, Spicer J, and Kassouf W. Nature communications 12 (1), 1-14.
Marcq G, Souhami L, Mansure JJ, Kassouf W. Phase I Trial of Atezolizumab + Trimodal Therapy in Patients with Bladder Cancer. IJROBP, 2021.
Rompré A, Shinde-Jadhav S, Ayoub M, Piccirillo C, Seuntjens J, Brimo F, Mansure J, Kassouf, W. PD-1/PD-L1 Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects. Mol Cancer Ther, 2020.
Ayoub M, Shinde-Jadhav S, Mansure J, Alvarez F, Connell T, Seuntjens J, Piccirillo C, Kassouf W. Immune mediated role of extracellular HMGB1 in bladder cancer radioresistance. Sci Rep, 2019.
Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W, Lotan Y, and Kassouf W. Bladder cancer. Lancet, 2016.